How GPCR-targeting therapies are advancing the fight against inflammatory disease
Drug Target Review
JUNE 16, 2025
In March 2025, Domain Therapeutics disclosed DT-9046 as an oral drug candidate for inflammatory diseases, including AD, IBD and arthritis, as well as pain. DT-9046 is currently progressing through pre-IND studies, supported by a robust data package, including head-to-head benchmarks and strong patent protection.
Let's personalize your content